Genzyme Corporation today reported strong sales and profit growth in the second quarter, along with significant progress in its commercial and clinical programs. More›

Genzyme Corporation and PTC Therapeutics, Inc. announced an exclusive global collaboration to develop and commercialize PTC124, PTC's novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations. More›

Genzyme and Isis Pharmaceuticals, Inc. announced the finalization of the license and collaboration agreement for mipomersen. The collaboration provides Genzyme with exclusive worldwide rights to mipomersen, a novel lipid-lowering drug discovered and developed by Isis that is in phase 3 clinical development. During the second half of this year, enrollment is expected to be completed in a pivotal study of mipomersen in homozygous familial hypercholesterolemia, and a new trial in apheresis-eligible patients is expected to begin. More›